The stock of The Medicines Company (NASDAQ:MDCO) is a huge mover today! About 7.40 million shares traded hands or 756.34% up from the average. The Medicines Company (NASDAQ:MDCO) has risen 13.77% since March 3, 2016 and is uptrending. It has outperformed by 5.42% the S&P500.
The move comes after 7 months negative chart setup for the $2.47 billion company. It was reported on Oct, 6 by Barchart.com. We have $32.26 PT which if reached, will make NASDAQ:MDCO worth $172.90 million less.
Analysts await The Medicines Company (NASDAQ:MDCO) to report earnings on November, 1. They expect $-1.48 EPS, down 64.44% or $0.58 from last year’s $-0.9 per share. After $-0.84 actual EPS reported by The Medicines Company for the previous quarter, Wall Street now forecasts 76.19% negative EPS growth.
The Medicines Company (NASDAQ:MDCO) Ratings Coverage
Out of 4 analysts covering The Medicines Co (NASDAQ:MDCO), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. The Medicines Co has been the topic of 11 analyst reports since August 28, 2015 according to StockzIntelligence Inc. The stock of The Medicines Company (NASDAQ:MDCO) has “Buy” rating given on Monday, March 21 by Chardan Capital Markets. The stock has “Market Perform” rating given by Oppenheimer on Monday, August 31. The stock has “Outperform” rating given by RBC Capital Markets on Monday, August 31. The firm earned “Buy” rating on Monday, August 31 by Leerink Swann. JP Morgan maintained The Medicines Company (NASDAQ:MDCO) on Saturday, August 29 with “Buy” rating. The firm has “Buy” rating by Chardan Capital Markets given on Wednesday, November 4. As per Monday, November 16, the company rating was maintained by RBC Capital Markets. The stock of The Medicines Company (NASDAQ:MDCO) has “Hold” rating given on Friday, August 28 by Jefferies.
According to Zacks Investment Research, “Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty. The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow.”
Insitutional Activity: The institutional sentiment increased to 1.27 in Q2 2016. Its up 0.14, from 1.13 in 2016Q1. The ratio improved, as 20 funds sold all The Medicines Company shares owned while 54 reduced positions. 25 funds bought stakes while 69 increased positions. They now own 81.19 million shares or 0.45% less from 81.56 million shares in 2016Q1.
Millennium Mgmt Limited Liability Company holds 0.09% or 1.21M shares in its portfolio. Blackrock has 7,348 shares for 0% of their US portfolio. The Illinois-based Northern Tru has invested 0.01% in The Medicines Company (NASDAQ:MDCO). Amer Century Incorporated holds 0% or 57,652 shares in its portfolio. Walleye Trading Ltd Liability has 0% invested in the company for 9,231 shares. Td Asset Mngmt last reported 0% of its portfolio in the stock. Wellington Mgmt Group Limited Liability Partnership accumulated 0.09% or 9.80 million shares. The Tennessee-based First Mercantile Tru has invested 0.01% in The Medicines Company (NASDAQ:MDCO). The California-based Whittier Trust has invested 0.04% in The Medicines Company (NASDAQ:MDCO). Manufacturers Life Insurance The has invested 0% of its portfolio in The Medicines Company (NASDAQ:MDCO). Pub Sector Pension Inv Board reported 48,926 shares or 0.02% of all its holdings. Us Financial Bank De accumulated 0% or 29,622 shares. Blackrock Advisors last reported 0% of its portfolio in the stock. Dai Ichi Life Ins accumulated 34,012 shares or 0.03% of the stock. Gemmer Asset Ltd has 133 shares for 0% of their US portfolio.
Insider Transactions: Since May 11, 2016, the stock had 3 insider purchases, and 8 insider sales for $10.34 million net activity. The insider Cox Christopher T bought 45,985 shares worth $1.74 million. Shares for $510,998 were sold by WYATT ELIZABETH H S on Wednesday, May 11. Savage Robert G. sold $369,500 worth of The Medicines Company (NASDAQ:MDCO) on Tuesday, May 24. MEANWELL CLIVE sold 10,000 shares worth $350,000. CROUSE WILLIAM had sold 15,000 shares worth $527,295 on Monday, May 16. Spigelman Melvin K sold 15,000 shares worth $555,000. ESHELMAN FREDRIC N also bought $10.10M worth of The Medicines Company (NASDAQ:MDCO) shares.
More notable recent The Medicines Company (NASDAQ:MDCO) news were published by: Foxbusiness.com which released: “Why The Medicines Company’s Share Price Got Sick Today” on October 06, 2016, also Reuters.com with their article: “BRIEF-The Medicines Company says provides update on PCSK9si study” published on October 05, 2016, Businesswire.com published: “The Medicines Company Provides Progress Update on Ongoing ORION-1 Study of PCSK9si” on October 05, 2016. More interesting news about The Medicines Company (NASDAQ:MDCO) were released by: Fiercebiotech.com and their article: “The Medicines Company sees shares slide on key trial not stopping early” published on August 31, 2016 as well as Benzinga.com‘s news article titled: “Mid-Day Market Update: Aurinia Pharmaceuticals Gains On AURION Data; Twitter …” with publication date: October 06, 2016.
MDCO Company Profile
The Medicines Company, incorporated on July 31, 1996, is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). The Company’s pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Firm sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. The Firm sells over three of its acute care generic products, including midazolam, ondansetron and rocuronium.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.